^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
DCC-3084
i
Other names: DCC-3084, DCC3084, DCC 3084
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Ono Pharma
Drug class:
pan-RAF inhibitor
Related drugs:
2ms
DCC-3084-01-001: Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway (clinicaltrials.gov)
P1/2, N=140, Active, not recruiting, Deciphera Pharmaceuticals, LLC | Recruiting --> Active, not recruiting
Enrollment closed
|
DCC-3084
over1year
DCC-3084-01-001: Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway (clinicaltrials.gov)
P1/2, N=140, Recruiting, Deciphera Pharmaceuticals LLC | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy • Metastases
|
DCC-3084
almost2years
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway (clinicaltrials.gov)
P1/2, N=140, Not yet recruiting, Deciphera Pharmaceuticals LLC
New P1/2 trial
|
DCC-3084
over2years
DCC-3084, a RAF dimer inhibitor, broadly inhibits BRAF class I, II, III, BRAF fusions, and RAS-driven solid tumors leading to tumor regression in preclinical models (AACR 2023)
The Switch Control inhibitor DCC-3084 broadly inhibits Class I, II and III BRAF mutations, BRAF fusions, and BRAF/CRAF heterodimers leading to tumor regression in preclinical models. The overall preclinical profile of DCC-3084 supports IND-enabling activities towards clinical development in a key area of unmet medical need in RAS and RAF mutant cancers.
Preclinical
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
|
KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RAS mutation • BRAF fusion • KRAS Q61K
|
DCC-3084
Share via
